PT  - JOURNAL ARTICLE
AU  - Roche, Nicolas
AU  - Nadif, Rachel
AU  - Fabry-Vendrand, Caroline
AU  - Pillot, Laura
AU  - Thabut, Gabriel
AU  - Teissier, Clément
AU  - Bouée, Stéphane
AU  - Zins, Marie
AU  - Goldberg, Marcel
TI  - Burden of asthma by treatment step in the French CONSTANCES general population cohort
AID  - 10.1183/13993003.congress-2021.PA3717
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3717
VI  - 58
IP  - suppl 65
4099  - https://publications.ersnet.org//content/58/suppl_65/PA3717.short
4100  - https://publications.ersnet.org//content/58/suppl_65/PA3717.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: Data on health care consumption and costs of asthma in the French population are scarce. CONSTANCES is a prospective general population cohort involving more than 200,000 volunteers.Objective: To describe the burden of asthma in France according to GINA treatment steps.Methods: Data (medical assessment & self-questionnaires) from participants included between 2012 and 2017 were extracted and linked to the French claim and hospitalization database (SNDS). Participants were considered as current asthmatics if asthma was reported at inclusion and asthma symptoms and/or treatments were present in 2017.Results: Among 120,000 participants, 5,296 asthmatics were identified and matched with 5,296 controls. Treatment step could not be categorized for 1,556 asthmatics due to lack of any treatment dispensation. Average annual cost of outpatient care was €1,960 versus €1,362 for participants without asthma. The frequency of asthmatics with symptoms, airflow limitation, cardiovascular risk factors and co-morbidities, outpatient visits and hospitalisations increased with GINA treatment steps, as well as inpatient and outpatient costs.Conclusion: The burden of asthma can be estimated at €600 per year and per patient on average in the population and increases with GINA treatment step, as well as the burden of symptoms and comorbidities.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3717.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).